Session 22 - 12th CROI

Home

Session 22 Oral Abstracts
Clinical Pharmacology: New Agents, Interactions, and Predictors of Virologic Response
Thursday, 10 am - 12:30 pm
Ballroom A

10:00 am 77	Prolonged Duration of CCR5 Occupancy by 873140 in HIV-negative and HIV-positive Subjects S Sparks, K Adkison, A Shachoy-Clark, S Piscitelli, and James Demarest* GlaxoSmithKline, Research Triangle Park, NC, USA
10:15 am 78	Pharmacodynamics of Antiretroviral Agents in HIV-1-infected Patients Using Viral Dynamic Models with Consideration of Drug Susceptibility and Adherence Hulin Wu*¹, Y Huang¹, E Acosta², J G Park³, S Yu³, S Rosenkranz³, D Kuritzkes⁴, J Eron⁵, A Perelson⁶, and J Gerber⁷ ¹Univ of Rochester Sch of Med and Dentistry, NY, USA; ²Univ of Alabama at Birmingham, USA; ³Frontier Sci & Tech Res Fndn, Boston, MA, USA; ⁴Partners AIDS Res Ctr, Cambridge, MA, USA; ⁵Univ of North Carolina at Chapel Hill, USA; ⁶Los Alamos Natl Lab, NM, USA; and ⁷Univ of Colorado Hlth Sci Ctr, Denver, USA
10:30 am 79	Steady-state Pharmacokinetics of Amprenavir, Lopinavir, and Efavirenz Combination in HIV-infected Patients Paul Pham*¹, P Barditch-Crovo¹, E Redpath¹, T Parson¹, W Khan¹, C Hendrix¹, K Carson¹, R Qaqish², and C Flexner¹ ¹Johns Hopkins Univ, Baltimore, MD, USA and ²Abbott Labs, Abbott Park, IL, USA
10:45 am 80	Minimum Plasma Concentrations of Nevirapine and Efavirenz in Relation to Virologic Failure in Antiretroviral-naive Patients F van Leth¹, B Kappelhoff², D Johnson³, M Losso⁴, A Boron-Kaczmarska⁵, M Saag⁶, J M Livrozet⁷, D Hall⁸, A Huitema², Ferdinand Wit*¹, J Beijnen², J Lange¹, and the 2NN Study group ¹Intl Antiviral Therapy Evaluation Ctr, Academic Med Ctr, Univ of Amsterdam, The Netherlands; ²Slotervaart Hosp, Amsterdam, The Netherlands; ³Marcia St Practice, Johannesburg, South Africa; ⁴Hosp JM Ramos, Buenos Aires, Argentina; ⁵Pomeranian Med Academy, Sczcecin, Poland; ⁶Univ of Alabama at Birmingham, USA; ⁷Edouard Herriot Hosp, Lyon, France; and ⁸Boehringer Ingelheim Pharma Inc, Ridgefield, CT, USA
11:00 am 81	Pharmacogenetics of Long-term Response to Efavirenz- and Nelfinavir-containing Regimens: NWCS213, an Analysis of ACTG 384 David W Haas*¹, L Smeaton², R Shafer³, G Robbins⁴, G Morse⁵, L Labbe⁶, G Wilkinson¹, D Clifford⁷, M Dube⁸, R D'Aquila¹, V DeGruttola², R Pollard⁹, A George¹, J Donahue¹, and R Kim¹ ¹Vanderbilt Univ, Nashville, TN, USA; ²Harvard Sch of Publ Hlth, Boston, MA, USA; ³Stanford Univ Sch of Med, CA, USA; ⁴Massachusetts Gen Hosp, Boston, USA; ⁵State Univ of New York at Buffalo, USA; ⁶Univ of Montréal, Canada; ⁷Washington Univ Sch of Med, St Louis, MO, USA; ⁸Indiana Univ Sch of Med, Indianapolis, USA; and ⁹Univ of California, Davis, Sch of Med, USA
11:15 am 82	An Open-label, Non-randomized Study of the Effect of Depo-medroxyprogesterone Acetate on the Pharmacokinetics (PK) of Selected Protease Inhibitors and Non-nucleoside Reverse Transcriptase Inhibitors Therapies among HIV-infected Women Susan Ellen Cohn*¹, D Watts², J Lertora³, J G Park⁴, S Yu⁴, and the A5093 Team ¹Univ of Rochester Med Ctr, NY, USA; ²NICHD, NIH, DHHS, Bethesda, MD, USA; ³Tulane Univ, New Orleans, LA, USA; and ⁴Harvard Sch of Publ Hlth, Boston, MA, USA